Bosun Asset Management’s Neuropace NPCE Stock Holding History

Bosun Asset Management’s Portfolio NPCE Stock Details NPCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-18,499	Closed	-$244K	–	187
2024 Q1	$244K	Buy	+18,499	New	+$264K	0.14%	167

Other funds holding NPCE

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

KLC

Kent Lake Capital Reno, Nevada $222M AUM 18.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bosun Asset Management's NPCE Position: Q2 2024 in Review

Bosun Asset Management sold out of Neuropace (NPCE) in Q2 2024, closing a stake of 18,499 shares — an estimated $244K sold.

Bosun Asset Management first reported a position in NPCE in Q1 2024 and held it in 1 quarter. The position peaked at $244K in Q1 2024. 51 funds tracked by Wall St. Rank hold NPCE as of Q2 2024.

Bosun Asset Management reported no remaining Neuropace position as of Q2 2024 after selling out during the quarter.
Bosun Asset Management sold 18,499 Neuropace shares in Q2 2024, an estimated $244K.
Bosun Asset Management first reported a position in Neuropace in Q1 2024 and held it in 1 quarter.
Bosun Asset Management's Neuropace position peaked at $244K in Q1 2024.
51 funds tracked by Wall St. Rank held Neuropace as of Q2 2024.

Based on Bosun Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.